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Immunosuppression with glucocorticoids is a common treatment for autoimmune liver diseases and after
liver transplant, which is however associated with severe side-effects. Targeted delivery of glucocorticoids
to inflammatory cells, e.g. liver macrophages and Kupffer cells, is a promising approach for minimizing
side effects. Herein, we prepare core–shell silica nanocapsules (SiO2 NCs) via a sol–gel process confined
in nanodroplets for targeted delivery of dexamethasone (DXM) for liver immunosuppressive therapy. DXM
with concentrations up to 100 mg mL−1 in olive oil are encapsulated while encapsulation efficiency
remains over 95% after 15 days. Internalization of NCs by non-parenchymal murine liver cells significantly
reduces the release of inflammatory cytokines, indicating an effective suppression of inflammatory
response of liver macrophages. Fluorescent and magnetic labeling of the NCs allows for monitoring their
intracellular trafficking and biodegradation. Controlled interaction with blood proteins and good colloidal
stability in blood plasma are achieved via PEGylation of the NCs. Specific proteins responsible for stealth
effect, such as apolipoprotein A-I, apolipoprotein A-IV, and clusterin, are present in large amounts on the
PEGylated NCs. In vivo biodistribution investigations prove an efficient accumulation of NCs in the liver,
underlining the suitability of the SiO2 NCs as a dexamethasone carrier for treating inflammatory liver
diseases.
Introduction
Liver diseases such as autoimmune hepatitis, primary biliary
cirrhosis, and primary sclerosing cholangitis are induced
by overwhelming inflammatory immune responses.
Immunosuppression with glucocorticoids is a common treat-
ment option for autoimmune liver diseases and after liver
transplant, even for pediatric patients.1 However, glucocorti-
coids do not act specifically on liver cells and their long-term
systemic administration is associated with severe side effects
such as osteoporosis, hypertension, hyperglycemia, adrenal
insufficiency, myopathy, metabolic disturbances, and stomach
and intestinal bleeding due to ulcers.2–4 Targeted delivery of
glucocorticoids to inflammatory liver cells, e.g. Kupffer cells
and macrophages, represents hence a promising approach for
increasing drug bioavailability in targeted tissue and organs
and reducing systemic adverse effects.5–9
Dexamethasone (DXM) is a very common glucocorticoid
drug.5 Although it is considered as one of the safest glucocorti-
coids, a broad spectrum of side effects have been still
observed; mostly due to its hydrophobicity.5 Sodium salt of
DXM was recommended as hydrophilic alternative of the drug,
but its use can lead to sodium overdosing.5 Water-soluble poly-
mers and nanoparticles have been used as drug carriers for
increasing the solubility of hydrophobic drugs.10 Because large
quantities of nanoparticles translocate to the liver by passive
targeting upon parenteral administration,11–13 nanocarrier-
mediated drug delivery represents a promising strategy for
combatting liver diseases.14
There are two main strategies for the controlled delivery of
DXM. In the first approach, DXM molecules were conjugated
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to hydrophilic polymers15–22 and nanoparticles23,24 via reac-
tions with ketone16–20,22,25,26 or hydroxyl20,21,23,27 groups of
DXM. The formed hydrazone or ester linkages allowed a
specific release of DXM in response to acidic local environ-
ment in inflammatory tissues. This approach relies on the
modification of polymers and/or the parent drug, and the
linker chemistry, and therefore multi-step synthesis and purifi-
cations are usually required. Alternatively, DXM compounds
can be directly loaded in nanoparticles. A variety of nano-
particles prepared from biodegradable polymers such as
PLGA,28–37 PLLA,38 PCL,38 cellulose,39 cyclodextrin,40 chito-
san,41 polyglutamic acid,42 or lipids43 and inorganic
materials,10,44 as well as polymer micelles,45 liposomes,46–49
and carbon nanotubes50 have been used to transport DXM.
Entrapment of DXM in nanoparticles led usually to a pro-
longed and sustained release of DXM.10,30–40,44,50 Nevertheless,
premature release of DXM before reaching the targeting
tissues is still an issue. In order to minimize side effects due
to leakage of drug and increase its bioavailability, an efficient
encapsulation and a selective release drug delivery system are
needed.
Furthermore, most of the DXM nano-formulations were
developed for topical therapies, e.g. the treatment of
ophthalmic,30,42,45,51 dermal,10,39 respiratory,32,52 bowel,43,53
brain,36,41 and joint diseases18,24,28,29,54–56 by local adminis-
tration. In this case, the nanoencapsulation is mainly used for
increasing local concentration of drugs and controlling their
release kinetics. However, intravenous administration of nano-
carriers is usually applied for treating liver diseases.9,13,57
Once the nanocarriers enter into the blood stream, various
blood components such as proteins and lipids rapidly interact
with nanocarriers and cover their surface.58,59 This bio-
molecular corona has been shown to be a key parameter that
mediates in vivo behavior of nanocarriers.60 Therefore, a sys-
tematic study on the interaction of DXM-nanocarriers with
blood proteins and the resulting colloidal stability and biodis-
tribution of nanocarriers are essential for assessing the effec-
tivity of nanocarrier-mediated targeted delivery.
In this study, we developed multifunctional core–shell silica
nanocapsules (SiO2 NCs) via an interfacially confined sol–gel
process for targeted delivery of DXM for liver immunosuppres-
sive therapy (Fig. 1). Silica nanomaterials show good biocom-
patibility, tunable porosity, and ease of surface modification.
Therefore, they have been widely studied for biological appli-
cations.61 The core–shell structure of the NCs enables high
encapsulation efficiency of DXM at high concentrations and an
intracellularly selective release upon biodegradation of the
shell. Controlled interactions with blood proteins and good
colloidal stability of the NCs in blood plasma were achieved by
PEGylation of the NCs, which are prerequisites for an effective
in vivo targeted delivery.
Results and discussion
Encapsulation of DXM in SiO2 NCs
DXM was encapsulated in the liquid core of the SiO2 NCs.
Hydrophobic DXM was first dissolved in olive oil at concen-
trations from 1 to 100 mg mL−1. The olive oil solution was
mixed with hexadecane, functional silica precursors, and iron
oxide nanoparticles (Fe3O4 NPs) to form the dispersed phase.
The hydrophobic mixtures were dispersed in an aqueous solu-
tion of the cationic surfactant cetyltrimethylammonium chlor-
ide (CTMA-Cl). The CTMA-Cl stabilized the miniemulsion dro-
plets against coalescence and confined the condensation of
silica precursors at the oil/water interface via a cooperative
Fig. 1 Schematic illustration of nanocarrier-mediated targeted delivery of dexamethasone for liver immunosuppressive therapy.
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assembly between negatively charged silica species with the
cationic surfactant.62 A silica shell was therefore formed
around nanodroplets containing DXM and Fe3O4 NPs.
63
Simultaneously, fluorescently modified silica precursors were
copolymerized in the silica network. Therefore, drug encapsu-
lation and fluorescent and magnetic labeling of NCs were
carried out in one step.
SiO2 NCs with an average hydrodynamic diameter of 144 ±
64 nm and ζ-potential of +12.2 ± 0.5 mV were obtained. Core–
Fig. 2 Colloidal characteristics of the SiO2 NCs. SEM micrographs of
the NCs, average number and surface density of CTMA-Cl and Lutensol
AT50 surfactant molecules, hydrodynamic diameter Dh, and zeta poten-
tial of the SiO2 NCs in water and plasma.
Fig. 3 (a) Uptake of SiO2 NCs with increasing concentrations by non-parenchymal liver cells in vitro evaluated by flow cytometry. All conditions
were compared to the negative control (without SiO2 NCs) and significance was given with p < 0.001 (*) (one-way ANOVA). (b) Cytotoxicity of SiO2
NCs measured by evaluating the number of propidium iodide positive cells by flow cytometry. (c) Effect of SiO2 NCs with increasing concentrations
on IL-6 secretion of NPCs after stimulation with 2.5 µg mL−1 LPS. All conditions were compared to the positive control (LPS stimulated) and signifi-
cance was given with p < 0.001 (*) (two-way ANOVAwith Dunnett’s multiple comparison test). Data represent mean ± SD (n = 3).
Fig. 4 Evolution of IL-6 secretion in non-parenchymal liver cells after
stimulation with 2.5 µg mL−1 LPS treated with SiO2 NCs containing
various concentrations of DXM. All conditions were compared to a posi-
tive control (LPS stimulated) and significance was given with p < 0.001
(*) (two-way ANOVAwith Dunnett’s multiple comparison test).
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shell morphology of the SiO2 NCs was identified by SEM and
TEM (Fig. 2), indicating a confined condensation of alkoxysi-
lanes around miniemulsion droplets. The average shell thick-
ness was determined to be 5 ± 2 nm from TEM micrographs.
Surface of the NCs was PEGylated by replacing the CTMA-Cl
with a PEG-based nonionic surfactant Lutensol AT50 by dialy-
sis. According to HPLC measurements performed to measure
the concentration of CTMA-Cl in the dialysis media, ∼90%
CTMA-Cl was removed. Remarkably, nanocapsules dispersions
were stable during the surfactant-exchange process. Size of
NCs increased slightly from 144 ± 64 nm for CTMA-Cl stabil-
ized NCs to 154 ± 67 nm for Lutensol AT50 stabilized NCs. The
surface charge of NCs turned from positive (+12.2 ± 0.5 mV) to
neutral (−0.1 ± 1.0 mV) after PEGylation. The slightly negative
charge was due to the dissociation of silanol groups at experi-
mental pH (4–5), which is above the isoelectric point of silica
(∼pH 2–3).62 Encapsulation efficiency of DXM in the PEGylated
NCs was subsequently investigated by dialyzing the nanocap-
sules dispersions. Less than 5% of DXM was released in 15
days (Fig. S1†), indicating a minimal leakage which is ben-
eficial for avoiding side effects from diffused free
corticosteroids.
Immunosuppression with SiO2-DXM NCs
Murine non-parenchymal liver cells were incubated with the
SiO2 NCs at various concentrations for 24 h. Cellular uptake of
NCs was quantified by using flow cytometry. A concentration-
dependent cellular uptake of NCs was observed (Fig. 3a). The
uptake increased from ∼5% to 28% as the concentration of
NCs increased from 10 to 100 µg mL−1 in cell culture. The cells
Fig. 5 Cellular uptake and localization of iron oxide labeled SiO2 NCs in HeLa cells based on TEM and elemental mapping techniques. TEM micro-
graphs of (a) Fe3O4 NPs labeled SiO2 NCs. (b) NCs that are entering cell membrane shown by yellow arrows. (c) NCs internalized in cell. (d–f )
Localization of NCs in intracellular environments after incubation for 2, 10, and 24 h. (g) Blue color represents signal of iron and red color represents
signal of silicon.
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were stained with propidium iodide for quantifying the popu-
lation of dead cells. The SiO2 NCs showed low effect on cell via-
bility especially at low concentrations, which is in line with
previous reports from other groups.64,65 Incubation with
100 µg mL−1 of NCs led to a slight increase of dead cells from
∼17% to 28% (Fig. 3b).
ELISA assays were performed to study the effect of encapsu-
lated DXM on interleukin-6 (IL-6) secretion of lipopolysacchar-
ide (LPS) stimulated non-parenchymal liver cells after 24 h
incubation in vitro. Treatment of the cells with SiO2-DXM NCs
led to a dose-dependent decrease of IL-6 secretion (Fig. 3c).
Incubation with 10 µg mL−1 SiO2-DXM NCs generated a ten-
fold reduction of secreted IL-6, showing an effect comparable
to the treatment with water-soluble DXM phosphate. One
advantage of nanocapsules over nanoparticle carriers is their
core–shell structure that offers a high encapsulation capacity.
DXM with concentrations ranging from 1 to 100 mg mL−1 in
olive oil was encapsulated as liquid core in SiO2 NCs, denoted
as SiO2-DXM1(−100) NCs in Table S1.† Average Dh of the SiO2-
DXM NCs was around 130–180 nm. Encapsulation efficiency of
DXM in NCs increased to ∼97% at loading concentration of
100 mg mL−1 in the core oil. As shown in Fig. 4, the suppres-
sion efficiency of SiO2-DXM NCs for IL-6 secretion was
enhanced significantly by increasing DXM loading content.
The suppression effects of SiO2-DXM NCs at internal loading
concentration of 50 and 100 mg mL−1 were comparable to
the water-soluble DXM phosphate at a concentration of 10
µg mL−1.
Cellular uptake behavior and intracellular trafficking of SiO2
NCs
Understanding cellular uptake, intra-, and intercellular
trafficking mechanisms of nanocarriers is critical for design-
ing efficient and safe nanomedicines.66 We studied the cellular
uptake behavior and intracellular trafficking of the SiO2 NCs
by TEM. However, because the SiO2 NCs have a core–shell
structure and size of ∼100 nm, they are difficult to distinguish
from cellular organelles on TEM micrographs. To overcome
this issue, we labeled the SiO2 NCs with Fe3O4 NPs as contrast
agent. Labeling of iron oxide also allowed the localization of
NCs by monitoring elemental distribution of silicon and iron.
As shown in Fig. 5a, the Fe3O4 NPs with diameter of ∼8 nm
were encapsulated in the inner core of NCs. To prove the
efficient loading of Fe3O4 NPs in NCs, gradient centrifugation
technique was applied. No free Fe3O4 NPs were separated from
the SiO2 NCs present in the upper phase (Fig. S2†), indicating
a high encapsulation efficiency of the NPs. By encapsulating
Fe3O4 NPs as contrast agent, SiO2 NCs were clearly distin-
guished from cellular organelles (Fig. 5b–e). Combined with
elemental mapping of silicon and iron obtained by electron
energy loss spectroscopy (EELS) and energy dispersive X-ray
spectroscopy (EDS), cellular uptake of the SiO2 NCs and their
localization in intracellular environment were successfully
identified (Fig. 5g). Intracellular trafficking of the NCs was
studied at different incubation times (Fig. 5c–f ). Iron oxide
labeled NCs were found in multivesicular bodies after 2 hours
incubation (Fig. 5d). After incubating the cells with magnetic
NCs for 10 and 24 h, some free Fe3O4 NPs, without surround-
ing silica shell, were observed (Fig. 5e and f). This observation
indicates a plausible intracellular degradation of the ultrathin
silica shell (∼5 nm), which is consistent with previous findings
from other groups. Chen et al. found that the degradation of
surfactant-extracted MCM-41-type mesoporous silica nano-
particles exhibited a very fast initial degradation within 2 h in
simulated body fluid.67 The incomplete –Si–O– tetrahedral
network in the nanoparticles, containing plenty of Si–R and
Si–OH groups, facilitated their easy degradation. Bein et al.
found that small particle size (50–70 nm) with a low conden-
Fig. 6 Schematic illustration of the aggregation state of SiO2 NCs stabilized with cationic surfactant CTMA-Cl and nonionic surfactant Lutensol
AT50.
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sation degree and a highly mesoporous texture (pore size
∼3–4 nm), and high surface area accelerated the degradation
reactions.68 In our case, the SiO2 NCs showed also a low con-
densation degree, as shown by the Q2 signal of 1%, Q3 signal
of 43%, and Q4 signal of 56% determined by
29Si MAS NMR
spectroscopy. The combination of the presence of free Si–R
and Si–OH groups with the thin shell and a pore size of
∼3–6 nm is therefore likely to facilitate the intracellular degra-
dation of the SiO2 NCs.
Protein interaction and colloidal stability of SiO2 NCs in blood
plasma
For successful in vivo application of nanocarriers as drug deliv-
ery vehicles, the nanocarriers need to remain colloidally stable
in blood plasma. With dynamic light scattering, it is possible
to directly monitor the aggregation state of nanocarriers in
concentrated blood plasma.69,70 This method is suitable for
screening the behavior of nanocarriers in blood plasma prior
to in vivo investigations. The SiO2 NCs stabilized by cationic
surfactant CTMA-Cl formed macroscopic aggregates in concen-
trated plasma. However, aggregation formation was signifi-
cantly reduced after PEGylation of the NCs with the PEG-based
nonionic surfactant Lutensol AT50 (Fig. 6). Surface charge of
the NCs was reduced from +12 mV to ∼0 mV due to the
removal of cationic surfactant (Fig. 2). With increased density
of PEG chains on the surface, the SiO2 NCs became more
stable in PBS and in blood plasma (Fig. S3†). Especially, going
from 0.64 to 0.96 PEG chains per nm2 resulted in a major
stability improvement, suggesting a certain threshold of
required surface PEG density. While some aggregates of
SiO2 NCs in blood plasma could still be observed after
PEGylation, the intensity contribution factor of these larger
species suggest that their actual concentration is very low com-
pared to stable NCs (Fig. S3b†). The exemplary autocorrelation
functions of the corresponding measured samples are given in
Fig. S4.†
Furthermore, it has been recognized in recent years that
various blood components such as proteins and lipids rapidly
interact with the nanocarriers and cover their surface upon
entering of the nanocarriers into blood plasma.58,59 This
process, coined ‘biomolecular corona formation’, has been
shown to be a key parameter that mediates in vivo behavior of
nanocarriers.60 As widely described in literature, PEGylated
nanocarriers have a prolonged blood circulation time caused
Fig. 7 Analysis of the protein corona. (a) Absolute amount of corona proteins on PEGylated and non-PEGylated SiO2 NCs determined by Pierce
Assay. (b) Zeta potential of SiO2 NC-PEG before or after incubation with blood plasma. (c) Isolated corona proteins identified by LC-MS. All proteins
were categorized into eight different classes based on their biological function. (d) Heatmap displaying the most abundant proteins in the protein
corona on SiO2 NCs before and after PEGylation. Only the proteins contributing to at least 1% of the protein corona on one of the nanocapsules are
shown. Relative values (%) were calculated based on the absolute amount of each protein (fmol). A detailed list of all identified proteins is sup-
plemented as Table S2.†
Paper Nanoscale



























































































by reduced protein adsorption, which subsequently induces a
lower cellular interaction with phagocytic cells (referred to as
‘stealth effect’).71,72 The PEGylated SiO2 NCs adsorbed a sig-
nificantly lower amount of plasma proteins (2.8 ± 0.3 mg per
m2 NC surface area) compared to non-PEGylated SiO2 NCs
(7.7 ± 0.2 mg per m2 NC surface area; Fig. 7a). However,
protein adsorption was not completely prevented, a phenom-
enon that was previously reported for PEGylated polystyrene
nanoparticles.73,74 Through a detailed proteomic investigation,
we were able to identify the key proteins that adsorbed onto
the SiO2 NCs after incubation in blood plasma (Fig. 7c and d).
We found that there was a significant change in the protein
pattern after PEGylation of SiO2 NCs. Indeed, there was an
overall increased amount of lipoproteins making up 76.4% of
the total protein corona content, which specifically adsorbed
to PEGylated SiO2 NCs in comparison to non-PEGylated cap-
sules (Fig. 7c).75 Especially, the relative amount of apolipopro-
tein A-I, apolipoprotein A-IV, and clusterin increased.
Clusterin, also known as apolipoprotein J, was identified as
major component of various PEGylated nanocarriers and it
was shown to display dysopsonic properties due to its ability to
reduce interaction with phagocytic cells.74,76 Apolipoprotein
A-I can substitute clusterin in this function.77–79 In contrast,
non-PEGylated SiO2 NCs were surrounded by fibrinogen,
which is a protein involved in blood coagulation and poten-
tially mediates the aggregation of nanocapsules.80 In our case,
the aggregation of CTMA-Cl stabilized NCs consequently most
likely originated from the fibrinogen interactions due to their
positively charged capsule surface.
The effect of protein corona on release profiles of drug
from Fe3O4 NPs, polymer NCs, and commercial nanocarriers
(Abraxane®, albumin-bound paclitaxel) was investigated.81
The protein corona was found to delay the release of drugs.
The drug release profile of nanocarriers depended on their
interaction with the protein corona, i.e. on the type and
amount of associated proteins in the hard corona, and on the
size/type of nanocarriers. The protein corona reduced the
burst release effect for protein-conjugated drug and carriers
with surface-loaded drug. However, drug release profiles of
polymer NCs were only slightly influenced by the protein
corona.
Next, we investigated the in vivo distribution of SiO2 NCs
after intravenous injection in mice. The SiO2 NCs were co-
valently labeled with the NIR fluorophore Cy7.5 at various
labeling densities (SiO2 NC-Cy7.5, NC-2 × Cy7.5, and NC-4 ×
Cy7.5) by coupling the amine-reactive molecular probe Cy7.5-
NHS with 3-aminopropyltriethoxysilane. Injected NCs were
accumulated in the liver at 30 min after intravenous injection
whereas no signal was detected in the other organs (Fig. 8a
and b). Total radiant efficiency of accumulated NCs in isolated
livers increased when the labeling density of fluorophores
increased in the NCs (Fig. 8c). This enrichment of nanocap-
sules in the livers underlines the suitability of SiO2 NCs as
dexamethasone carrier for the treatment of inflammatory liver
diseases such as alcoholic hepatitis, which are standardly
treated with glucocorticoids.82
Conclusions
We developed core–shell silica nanocapsules displaying
efficient and targeted delivery of dexamethasone for liver
immunosuppressive therapy. The oil core could dissolve DXM
at concentrations up to 100 mg mL−1 while the encapsulation
efficiency was kept over 95% after 15 days. Therefore, side
effects from premature leakage of DXM are expected to be sig-
nificantly reduced. The SiO2-DXM NCs showed an effective
suppression of inflammatory response of liver macrophages by
reducing the secretion of inflammatory cytokines. Intracellular
trafficking and degradation of NCs were investigated by label-
Fig. 8 IVIS imaging of in vivo distribution of SiO2 NCs labeled with
Cy7.5 observed at 30 min after intravenous injection in C57BL6/albino
mice. (a) Epi-illumination image of mice. (b) Ex vivo imaging of separate
organs. (c) Total radiant efficiencies of accumulated NCs in isolated
organs. Data represent mean (n = 1).
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ing them with fluorescent dyes and magnetic nanoparticles.
By a simple PEGylation process, controlled interactions with
blood proteins and good colloidal stability of NCs in blood
plasma were achieved with an efficient accumulation in the
liver. The efficient encapsulation, multimodal labeling, con-
trolled protein interaction, colloidal stability in blood, and
enrichment in the liver underline the suitability of the SiO2




Tetraethoxysilane (TEOS, Alfa Aesar, 98%), 3-aminopropyl-
trimethoxysilane (APTES, Alfa Aesar, >98%), hexadecane
(Sigma Aldrich, 99%), olive oil (Sigma Aldrich, highly refined,
low acidity), cetyltrimethylammonium chloride (CTMA-Cl,
Acros Organics, 99%), Lutensol AT50 (BASF), dexamethasone
(DXM, Sigma Aldrich, ≥98%), and sucrose (Sigma Aldrich,
≥99.5%) were used as received. Amine-reactive fluorescent
dyes Cyanine5 NHS ester (Cy5-NHS) and Cyanine7.5 NHS ester
(Cy7.5-NHS) were purchased from Lumiprobe GmbH,
Germany. Human citrate plasma was obtained from the
Department of Transfusion Medicine Mainz from ten healthy
donors, pooled and stored at −80 °C. Prior to use, human
plasma was centrifuged for 30 min at 20 000g (4 °C) to remove
aggregated proteins. Oleic acid capped iron oxide nano-
particles (Fe3O4 NPs) were synthesized according to a standard
co-precipitation protocol.83
Synthesis of SiO2 NCs
SiO2 NCs were synthesized in an oil-in-water miniemulsion by
using the surface of oil nanodroplets as template for the
hydrolysis and condensation of alkoxysilanes. Specifically,
2.0 g (9.6 mmol) of TEOS was first mixed with 125 mg of hexa-
decane and 1 g of olive oil to form the oil phase. For cargo
loading, various amounts of DXM or iron oxide nanoparticles
were first dissolved in olive oil. In the second step, 30 mL of
0.77 mg mL−1 aqueous solution of CTMA-Cl was poured into
the oil mixture under stirring. After a pre-emulsification step
by stirring at 1000 rpm for 1 h, the obtained emulsion was
sonicated by using a Branson 450 W sonifier with a 1/2″ tip at
70% amplitude for 180 s (30 s of sonication, 10 s of pause)
with ice cooling. The resulting miniemulsion was stirred at
1000 rpm for 12 h at room temperature to obtain an aqueous
dispersion of SiO2 NCs. For the fluorescent labeling of SiO2
NCs, Cy5-NHS or Cy7.5-NHS was first coupled with APTES at
a molar ratio of 1 : 1.1 to obtain fluorescently labeled silica
precursors. The APTES-Cy5/7.5 conjugates were then mixed
with TEOS as the silica source. The molar ratio of Cy5 with
TEOS was 1 : 14 000. For in vivo experiments, the molar ratio
of Cy7.5 to TEOS was set as 1 : 14 000, 1 : 7000, and 1 : 3500
for samples SiO2 NC-Cy7.5, NC-2 × Cy7.5, and NC-4 × Cy7.5,
respectively.
PEGylation of SiO2 NCs and encapsulation efficiency of DXM
SiO2 NCs were PEGylated by replacing the templating surfac-
tant CTMA-Cl by the nonionic surfactant Lutensol AT50.
PEGylated nanocapsules were denoted as SiO2 NC-PEG.
Specifically, 35 mg of Lutensol AT50 was added to 2 mL of
SiO2 NCs dispersion. The dispersion was stirred at 1000 rpm
for 2 h and then dialyzed against water with a dialysis tube
with MWCO of 1000 g mol−1. In this case, CTMA-Cl (Mw =
320 g mol−1) could diffuse through the dialysis membrane into
the aqueous dialysis medium while Lutensol AT50 (Mw =
2460 g mol−1) was kept inside. Dialysis media were changed
three times per day until no DXM and CTMA-Cl were detected
in the media by UV-Vis spectroscopy and HPLC, respectively.
Encapsulation efficiency of DXM in NCs was expressed as the
percentage of encapsulated DXM with respect to the initial
amount of DXM. The calibration curve for the determination
of DXM in water is shown in Fig. S5.† Afterwards, the dialyzed
dispersion was centrifuged at 10k rpm to remove the excess of
Lutensol AT50. The pellet was redispersed in water and the dis-
persion was stirred at 1000 rpm for 24 h.
Protein corona analysis
Protein corona preparation. Nanocapsules with a total
surface area of 0.05 m2 were incubated in 1 mL of human
citrate plasma for 1 h at 37 °C under constant agitation (300
rpm).74,84 Protein coated nanocapsules were isolated via cen-
trifugation (20 000g, 1 h, 4 °C) and redispersed in PBS (1 mL).
To remove loosely bound and unbound proteins, this purifi-
cation procedure was repeated three times. Before the final
washing step, the dispersion was transferred into a new
Eppendorf-tube. After the last centrifugation step, the nano-
capsule pellets were resuspended in a solution containing
2 wt% SDS and 62.5 mM Tris*HCl. The suspension was incu-
bated at 95 °C for 5 min to detach the corona proteins. The
sample was then centrifuged (20 000g, 1 h, 4 °C) and the super-
natant was taken for protein corona analysis.
Protein quantification. Protein content of the corona was
determined via Pierce 660 nm protein Assay (Thermo
Scientific) using bovine serum albumin as standard. The
absorption was measured at 660 nm with a Tecan infinite
M1000 plate reader.
Liquid chromatography-mass spectrometry (LC-MS) analysis.
Proteomic analysis was carried out as previously described.84,85
Briefly, SDS was removed from the protein sample via Pierce
Detergent Removal Spin Columns (Thermo Fisher). Further,
proteins were precipitated using ProteoExtract protein precipi-
tation kit (CalBioChem) overnight. Afterwards, the protein
pellets were isolated via centrifugation (14 000g, 10 min) and
resuspended with RapiGest SF (Waters) in ammonium bicar-
bonate (50 mM). The protein solution was reduced with dithio-
threitol (Sigma) at a concentration of 5 mM for 45 min at 56 °C
and alkylated with 15 mM idoacetoamide (Sigma) for 1 h in
the dark. Tryptic digestion (protein : trypsin ratio 50 : 1) was
carried out for 18 h at 37 °C. Afterwards, the reaction was
quenched with 2 µL hydrochloric acid (Sigma).
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Tryptic peptides were diluted with 0.1% formic acid spiked
with 50 fmol µL−1 Hi3 E. coli (Waters) for absolute protein
quantification. The peptide solution was injected into a
nanoACQUITY UPLC system coupled to a Synapt G2-Si mass
spectrometer. The system was operated in resolution mode,
with a NanoLockSpray source in positive ion mode. Data-inde-
pendent acquisition (MSE) experiments were performed and
data was analyzed with MassLynx 4.1.
Proteins were identified with Progenesis GI (2.0) using a
reviewed human database downloaded from Uniprot. For ana-
lysis, the following criteria were chosen: max. protein mass
600 kDa, one missed cleavage, fixed modifications for carba-
midomethyl and cysteine, variable oxidation for methionine,
and a false discovery rate of 4%. Peptide identification requires
three identified fragments and for proteins identification five
identified fragments and two peptides are needed. Based on
the TOP3/Hi3 quantification the amount of each protein in
fmol is provided.86 All identified proteins are summarized in a
separate Excel file as ESI.†
TEM analysis
Sapphire disks (3 mm; M. Wohlwend GmbH) were pre-coated
with a 10 nm-thick carbon layer using an EM MED020 instru-
ment (Leica). The coated sapphire disks were dried and steri-
lized in an oven at 120 °C overnight before use. HeLa cells
were seeded onto sapphire disks in 12-well plates overnight for
cell attachment. SiO2 NCs (loaded with Fe3O4 NPs) were incu-
bated with HeLa Cells at 75 µg ml−1 for 2 h, 10 h, and over-
night in a humidified incubator at 37 °C and 5% CO2. After
the incubation, each sapphire disk was collected from the
12-well plates and slightly immersed into 1-hexadecene before
placing them between two aluminum plates (3 mm, Plano).
This “sandwich” structure was placed into a specimen holder
for high pressure freezing in a Wohlwend HPF Compact
01 high pressure freezer with a pressure of 2100 bar for 2–3 s.
The specimen holder was withdrawn from the freezer and
immersed into liquid nitrogen to release the sample. The
frozen sample was then labeled and stored in a container filled
with liquid nitrogen. Subsequently, freeze substitution of the
sample was carried out in a 0.5 ml Eppendorf tube using an
AFS2 automated freeze substitution device (Leica). Each tube
contained 1 ml of freeze substitution solution, consisting of
0.2 wt/vol% osmium tetroxide, 0.1 wt/vol% uranyl acetate, and
5% distilled water in acetone. The tubes were firstly kept at
−90 °C and slowly warmed up to 0 °C in 24 h. After keeping at
room temperature for 1 h, the substitution solution was
removed and the samples were washed 3 times with acetone.
Each sample was infiltrated in an ascending epoxy resin series
(30%, 50%, and 75% in acetone) for 1 h before finally infiltra-
tion in 100% epoxy resin overnight. Finally, each sample was
transferred into a new Eppendorf tube containing freshly pre-
pared pure epoxy resin for polymerization at 60 °C for 24 h.
After polymerization, sample blocks were kept at room temp-
erature until their sectioning. Sample blocks for each time
point were trimmed and sectioned into 100 nm sections by a
45° diamond knife (Diatome) in EM UC6 ultramicrotome
(Leica). Sections were then carefully placed onto 300-mesh
copper grid for standard bright-field, electron energy loss spec-
troscopy (EELS), and energy dispersive X-ray spectroscopy
(EDX) analysis in Tecnai F20 200 kV transmission electron
microscope (TEM) (FEI). Bright-field TEM micrographs were
obtained with a Gatan US1000 2k CCD camera. EDX images
were collected with an EDAX detector.
Isolation of non-parenchymal liver cells and stimulation with
SiO2 NCs
Six to eight-week old female C57BL/6J mice were obtained
from Janvier (Le Genest-Saint-Isle, France). All mice were kept
under a 12 h dark/12 h light cycle (with food and water supply
ad libitum) in the animal facility of the Translational Animal
Research Center, University Medical Center Mainz, Germany.
The animals were treated in accordance with NIH publications
entitled “Principles for Use of Animals” and “Guide for the
Care and Use of Laboratory Animals”. All protocols have been
approved by the local Animal Care and Use Committee
(“Landesuntersuchungsamt Rheinland-Pfalz”). The murine
non-parenchymal liver cells (NPCs) were isolated from livers as
previously reported.87,88 Briefly, mice were anesthetized with
Ketamin/Rompun and livers were perfused with cold 20 ml
Ca2+- and Mg2+-free Hank’s Balanced Salt Solution (HBSS;
Sigma-Aldrich, St Louis, USA) containing 100 U l−1 collagenase
A (Roche Diagnostics GmbH, Mannheim, Germany), 5% heat-
inactivated fetal calf serum (FCS, GE Healthcare Life Sciences,
Chalfont St Giles, UK), and 10 µg ml−1 DNase I (AppliChem,
Darmstadt, Germany). Following dissection, the livers were
incubated for 15 min at 37 °C and grinded through a 70 µm
cell strainer to generate single cell suspensions. Hepatocytes
were pelleted and discarded after centrifugation for 15 min at
4 °C and 30g. The non-parenchymal cell fraction remaining in
the supernatant was further purified by centrifugation at 300g,
resuspended in Histodenz solution in HBSS to reach a final
concentration of 20% and overlaid with HBSS, followed by cen-
trifugation at 1500g for 20 min. NPCs were collected at
the Histodenz/HBSS interface and washed with RPMI
1640 medium containing 5% FCS and 1% penicillin/strepto-
mycin. The cell suspension was then cultured in HEPES-
buffered RPMI 1640 medium containing 10% FCS, 1% penicil-
lin/streptomycin, 1 mM L-glutamine, 1% essential and non-
essential amino acids, 1 mM sodium pyruvate, 50 nM
β-mercaptoethanol, and with or without 2.5 µg ml−1 lipopoly-
saccharide (LPS) at concentration of 106 NPCs ml−1. Different
formulations of SiO2 NCs containing cy5 or DXM as well as
soluble DXM-phosphate were added at different concen-
trations and incubated for 24 h as indicated.
Toxicity and uptake of SiO2 NCs and cytokine secretion
Toxicity and uptake of SiO2 NC by NPCs was analyzed by propi-
dium iodide (PI, BD Pharmingen) staining (5 µl per sample)
and subsequent flow cytometric quantification (BD LSR II) of
PI and NC positive cells. Interleukin-6 (IL-6) levels in cell
culture supernatants were analyzed using an enzyme-linked
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immunosorbent assay kit (ThermoFisher) according to manu-
facturer’s instructions.
In vivo imaging of SiO2 NCs
C57BL6/Albino mice were depilated at the abdominal and
thoracic zone and the corresponding dorsal areas 400 µg of
SiO2 NCs labeled with increasing concentrations of Cy7.5 were
injected intravenously and mice were analyzed 30 min after
injection using the IVIS SpectrumCT imager (PerkinEllmer,
Waltham, USA) and the Living Image Software 4.5.
Subsequently, mice were sacrificed and the organs (liver,
spleen, kidneys, lungs, heart) were isolated and analyzed
again.
Characterization
Hydrodynamic diameters of SiO2 NCs were measured by
dynamic light scattering (DLS) with a Nicomp particle sizer
(Model 380, PSS, Santa Barbara, CA) at a fixed scattering angle
of 90°. The morphology of nanocapsules was examined with a
Gemini 1530 (Carl Zeiss AG, Oberkochem, Germany) scanning
electron microscope (SEM) operating at 0.35 kV and a Jeol
1400 (Jeol Ltd, Tokyo, Japan) transmission electron microscope
operating at an accelerating voltage of 120 kV. SEM and TEM
samples of nanocapsules were prepared by casting the diluted
dispersions on silicon wafers and carbon layer-coated copper
grids, respectively. The capsule dispersions were dialyzed
against Milli-Q water for 3 days to remove the surfactant. The
dialyzed dispersions were then freeze-dried for 48 h and
degassed at 70 °C under high vacuum for at least 12 h before
measurements. The specific surface area was calculated using
the Brunauer–Emmett–Teller (BET) equation based on data
points obtained from 0 < P/P0 < 0.25. Zeta potential measure-
ments were performed in 10−3 M potassium chloride solution
at pH 6.8 and 25 °C with a Malvern Zeta sizer (Malvern
Instruments, UK). Solid content of the capsule dispersion was
measured gravimetrically. Quantitative 29Si MAS-NMR spectra
were recorded with a Bruker Avance II spectrometer according
to our previous work.89 Numbers of CTMA-Cl and Lutensol
AT50 molecules per NC and per nm2 surface were calculated
by dividing the number of surfactant molecules by the number
and total surface area of NCs, respectively. The number of NCs
in dispersion was determined based on the solid content of
the dispersion and the mass of single NC. Multiangle DLS
measurements were performed using an instrument from ALV
(Langen, Germany) with an electronically controlled goni-
ometer and an ALV-5000 multiple τ full-digital correlator with
320 channels for measurements in the range between 10−7 s
and 103 s. The source of light was a helium–neon laser of the
Type 1145 P from JDS Uniphase (Milpitas, USA) with 632.8 nm
wavelength and 25 mV output power. Before the measure-
ments, PBS or undiluted human plasma was filtered through
Millex-LCR filters (Merck Millipore, Billerica, USA) with
450 nm pore size into quartz cuvettes with an inner radius of
9 mm for light scattering from Hellma (Müllheim, Germany).
After filtration of the eluent, 2 µL of the NC dispersions
(30 mg mL−1) were added. Prior to use, the quartz cuvettes
were cleaned with acetone using a Thurmond apparatus.90 For
data analysis, a robust multicomponent fit method reported by
Rausch et al.70 was used. UV-Vis absorption spectra of DXM
solution were recorded with a PerkinElmer Lambda 25 UV-Vis
spectrometer. Gradient centrifugation experiments were per-
formed at 4 °C and 5000 rpm for 3 h in a Rotixa 50RS ultracen-
trifuge, Hettich. Sucrose solutions with densities ranging
between 1.00 and 1.30 g cm−3 were used.
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